This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications Open Access 18 January 2021
-
Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells
Cell Death & Disease Open Access 03 May 2018
-
Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Leukemia Open Access 22 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21: 158–163.
Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury Cappellesso S et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079–1088.
Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007; 48: 2032–2041.
Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009; 23: 1515–1527.
Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997; 76: 451–460.
Meirelles Lda S, Nardi NB . Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol 2003; 123: 702–711.
Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67: 7665–7674.
Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007; 109: 3024–3030.
Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160–3165.
Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P et al. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011; 25: 1174–1181.
Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E . Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 2008; 149: 3890–3899.
Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008; 14: 306–314.
Zanotti S, Smerdel-Ramoya A, Canalis E . HES1 (hairy and enhancer of split 1) is a determinant of bone mass. J Biol Chem 2011; 286: 2648–2657.
Engin F, Lee B . NOTCHing the bone: insights into multi-functionality. Bone 2010; 46: 274–280.
He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. Mol Oncol 2011; 5: 292–301.
Acknowledgements
We would like to thank Nicole Arras, Angelo Willems, Veerle De Greef, Carin Seynaeve and Orla Gallagher for their expert technical assistance and Professor Zhou Qinghua for his administrative support. Our research work is supported by grants from the FWO-Vlaanderen, Vlaamse Liga tegen Kanker (Stichting Emmanuel Van der Shueren), the Vrije Universiteit Brussel (HOA) and the Scientific Foundation Willy Gepts (WFWG) UZ Brussel. Xu S is supported by CSC-VUB scholarship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Xu, S., Evans, H., Buckle, C. et al. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia 26, 2546–2549 (2012). https://doi.org/10.1038/leu.2012.126
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.126
This article is cited by
-
Mesenchymal stromal cell senescence in haematological malignancies
Cancer and Metastasis Reviews (2023)
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications (2021)
-
Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells
Cell Death & Disease (2018)
-
Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche
Leukemia (2018)
-
Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Leukemia (2018)